Page last updated: 2024-12-11
silatrane
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
silatrane: RN given refers to unspecified silatrane [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 6328633 |
CHEMBL ID | 1992781 |
SCHEMBL ID | 311425 |
MeSH ID | M0064815 |
Synonyms (13)
Synonym |
---|
silatrane |
4,6,11-trioxa-1-aza-5-silabicyclo[3.3.3]undecane |
2,8,9-trioxa-5-aza-1-silabicyclo[3.3.3]undecane |
NCI60_008396 |
2,8,9-trioxa-5-aza-1-silabicyclo(3.3.3)undecane |
einecs 206-004-0 |
283-60-3 |
AKOS006272947 |
unii-gr8p7y2mzw |
gr8p7y2mzw , |
SCHEMBL311425 |
DTXSID0058352 |
CHEMBL1992781 |
Research Excerpts
Treatment
Excerpt | Reference | Relevance |
---|---|---|
"The silatrane-treated animals were either free of palpable tumors or developed tumors much more slowly in comparison with the control animals without silatranes." | ( Antitumor effect of novel silatranes on renal cell carcinoma in mice. Grna, A; Hogan, J; Koo, PH, ) | 0.91 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (22)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 8 (36.36) | 18.7374 |
1990's | 2 (9.09) | 18.2507 |
2000's | 4 (18.18) | 29.6817 |
2010's | 6 (27.27) | 24.3611 |
2020's | 2 (9.09) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 30.90
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (30.90) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (3.03%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 32 (96.97%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |